Synaffix BV
Synaffix BV is a Netherlands-based biotechnology company focused on developing industry-leading antibody-drug conjugate (ADC) technology platforms. Its mission is to enable best-in-class targeted cancer therapeutics through its versatile glycoprotein modification technology, aiming to broaden the therapeutic index and improve safety and potency of ADCs. Synaffix's vision is to be the preferred technology partner for developing superior targeted cancer therapeutics, with first-in-human glycan-conjugated ADCs expected in 2016. The company is backed by top-tier investors including Aravis, BioGeneration Ventures, BOM Capital, and MS Ventures, the strategic venture arm of Merck Serono.
Industries
Nr. of Employees
small (1-50)
Synaffix BV
Patents
Modified antibody, antibody-conjugate and process for the preparation thereof
US-12194107-B2
View DetailsProcess for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne
US-12084448-B2
View DetailsProcess for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase
US-12049656-B2
View Details
Modified antibody, antibody-conjugate and process for the preparation thereof
US-12194107-B2
View DetailsProcess for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne
US-12084448-B2
View DetailsProcess for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase
US-12049656-B2
View DetailsProducts
Site-specific antibody conjugation platform (glycan-directed)
A chemoenzymatic platform that remodels the native antibody glycan and uses metal-free click chemistry to attach payloads, producing homogeneous ADCs across IgG isotypes without antibody engineering.
Linker-payload portfolio (multi-mechanism)
A set of linker-payload constructs spanning multiple mechanisms (topoisomerase inhibitors, DNA-damaging agents, microtubule inhibitors, maytansinoids) designed for integration with the glycan-directed conjugation platform and matched to DAR formats.
Protein-conjugates and immune recruiter constructs
Custom conjugation of protein-based payloads (e.g., scFv, Fab, cytokines, anti-CD3, IL-15 constructs) to antibodies for bispecific or immune-recruiting applications.
GlycoConnect
A site-specific ADC conjugation platform that easily matches payload potency with the most appropriate drug-antibody ratio.
HydraSpace® Polar Spacer
A polar spacer technology forming an integral part of every toxSYN linker-payload, bearing a negative charge at physiological pH to improve therapeutic efficacy, tolerability, PK, and manufacturability.
toxSYN
A linker-payload platform offering modular attachment options under technology evaluation for ADC product development.
Site-specific antibody conjugation platform (glycan-directed)
A chemoenzymatic platform that remodels the native antibody glycan and uses metal-free click chemistry to attach payloads, producing homogeneous ADCs across IgG isotypes without antibody engineering.
Linker-payload portfolio (multi-mechanism)
A set of linker-payload constructs spanning multiple mechanisms (topoisomerase inhibitors, DNA-damaging agents, microtubule inhibitors, maytansinoids) designed for integration with the glycan-directed conjugation platform and matched to DAR formats.
Protein-conjugates and immune recruiter constructs
Custom conjugation of protein-based payloads (e.g., scFv, Fab, cytokines, anti-CD3, IL-15 constructs) to antibodies for bispecific or immune-recruiting applications.
GlycoConnect
A site-specific ADC conjugation platform that easily matches payload potency with the most appropriate drug-antibody ratio.
HydraSpace® Polar Spacer
A polar spacer technology forming an integral part of every toxSYN linker-payload, bearing a negative charge at physiological pH to improve therapeutic efficacy, tolerability, PK, and manufacturability.
toxSYN
A linker-payload platform offering modular attachment options under technology evaluation for ADC product development.
Services
Short-term evaluation projects to apply the glycan-targeted conjugation workflow and linker-payload chemistries to partner antibodies to assess feasibility and early POC.
Per-target licensing of platform conjugation technology and linker-payloads with options for further target-specific licenses, including milestones and royalties.
Provision of defined linker-payload constructs and integration of custom payloads into the conjugation workflow for partner ADC programs.
Attachment of peptide and protein-based payloads or immune-cell recruiter modules to antibodies using glycan-directed conjugation methods.
Design and execution of comparative preclinical efficacy and toxicology studies to benchmark ADC performance versus alternative conjugation approaches.
Short-term evaluation projects to apply the glycan-targeted conjugation workflow and linker-payload chemistries to partner antibodies to assess feasibility and early POC.
Per-target licensing of platform conjugation technology and linker-payloads with options for further target-specific licenses, including milestones and royalties.
Provision of defined linker-payload constructs and integration of custom payloads into the conjugation workflow for partner ADC programs.
Attachment of peptide and protein-based payloads or immune-cell recruiter modules to antibodies using glycan-directed conjugation methods.
Design and execution of comparative preclinical efficacy and toxicology studies to benchmark ADC performance versus alternative conjugation approaches.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Bioconjugation chemistry
- Linker-payload design and synthesis
- Metal-free click chemistry and SPAAC
Key Technologies
- Glycan-targeted site-specific conjugation
- Metal-free click chemistry (strain-promoted azide–alkyne cycloaddition)
- Polar spacer chemistries to improve payload solubility/stability
- Linker-payload libraries covering topoisomerase inhibitors, DNA-damaging agents, auristatins, maytansinoids
News & Updates
Synaffix will present its latest technological advancements, including HydraSpace™, at the BIO Europe Spring Conference in Paris.
Synaffix will present three posters related to its proprietary ADC technology at the AACR Annual Meeting in Chicago.
Synaffix was recognized as the runner-up for the best platform technology at the 4th Annual World ADC Awards.
Synaffix expanded its Scientific Advisory Board with Dr. John Lambert, former CSO of ImmunoGen.
Preclinical studies show Synaffix's technology generates ADCs with a better therapeutic index than Kadcyla and Adcetris.
Synaffix granted a license to ADC Therapeutics for its GlycoConnect™ and HydraSpace™ technologies.
Synaffix will present its latest technological advancements, including HydraSpace™, at the BIO Europe Spring Conference in Paris.
Synaffix will present three posters related to its proprietary ADC technology at the AACR Annual Meeting in Chicago.
Synaffix was recognized as the runner-up for the best platform technology at the 4th Annual World ADC Awards.
Synaffix expanded its Scientific Advisory Board with Dr. John Lambert, former CSO of ImmunoGen.
Preclinical studies show Synaffix's technology generates ADCs with a better therapeutic index than Kadcyla and Adcetris.
Synaffix granted a license to ADC Therapeutics for its GlycoConnect™ and HydraSpace™ technologies.